Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$81.3M
52M shares
52-week range
$1.42 – $3.35
5% from low
Exchange
NASDAQ
CS
Borrow rate
4.76%
Moderate
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
www.okyopharma.comNo one on the platform currently holds OKYO.
No tracked institution reports a position in OKYO as of their last filing.
No one on the platform has traded OKYO yet.
$OKYO Dr. Gary Jacob indeed stepped down as CEO of OKYO Pharma in January 2025. Since then, Dr. Raj Patil has been leading the company's operational business as CEO and President. Although Gary Jacob is still active in the background as a strategic advisor, he no longer holds the executive chair.
View on StockTwits ↗$OKYO This company is absolutely doomed with Gary Jacob. Look at his previous track record. He has destroyed shareholder value everywhere he goes. Feel bad for anyone holding shares here
View on StockTwits ↗@SuperGreenToday what does it means ? What is your view in $OKYO ?
View on StockTwits ↗$OKYO Get your Cheepies Soon!!! These prices will not Last.
View on StockTwits ↗$OKYO Potential near-term catalysts for investors include completion of protocol finalisation, site identification and study activation activities. Dempsey said the company expects to achieve first patient first visit milestones within the next three to six months as the clinical program progresses.
View on StockTwits ↗$OKYO CEO Robert Dempsey said Sacchetti’s combination of clinical, academic and industry expertise would strengthen the company’s position as it progresses its clinical plans in the United States and Europe. Dempsey described neuropathic corneal pain as a “severe, debilitating condition” that remains significantly under researched and currently has no FDA-approved treatment options. He said OKYO Pharma is seeking to pioneer a new ocular therapeutic category through its lead candidate Urcosimod.
View on StockTwits ↗$OKYO Lots of Talent but we need to start Recruiting for this Six month Trial.
View on StockTwits ↗$OKYO OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board Sacchetti is an associate professor of ophthalmology at Link University in Rome. According to the company, she brings extensive clinical, research, and industry experience in cornea and ocular surface diseases, including prior leadership as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici. OKYO noted that Sacchetti’s experience in targeted nerve regeneration, pain signaling modulation, and advanced diagnostics will support its development efforts in neuro-inflammatory eye disease.
View on StockTwits ↗$OKYO OKYO Pharma Limited Sponsored ADR (OKYO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
View on StockTwits ↗$OKYO Knock down that Wall Mr Gorbachev. Need news update to take out that 1.70 level. Let’s Start this Sux Month Trial Already. Stop with the Worthless Presentations.
View on StockTwits ↗$OKYO Should be getting Updates on New Trial Recruitment soon as they are Targeting Mid Year Start.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.